Kappos L, Bates D, Edan G et al.
University Hospital, Basel, Switzerland.
Lancet Neurol 2011;10:745–58.
Editor’s note: Natalizumab is recommended for patients with multiple sclerosis (MS) that does not respond to first-line disease-modifying therapies or for those who have highly active disease. In this review, the authors provide advice on safety monitoring and recommendations for the diagnosis and management of the most serious side-effect of this drug, progressive multifocal leukoencephalopathy (PML).